MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
893.07%
Quick Ratio
893.07%
Cash Ratio
209.56%
Debt to Asset Ratio
101.54%
Unit: Thousand (K) dollars
Assets Breakdown
    • Investments
    • Cash and cash equivalents
    • Intangible assets, net
    • Others
Liabilities Breakdown
    • Convertible notes
    • Accumulated deficit
    • Additional paid-in capital
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
182,049
145,191
165,703
74,252
Investments
571,995
241,873
275,794
380,726
Prepaid clinical trial costs
12,996
15,374
18,896
-
Other current assets
8,801
6,491
5,266
20,519
Total current assets
775,841
408,929
465,659
475,497
Total property and equipment, gross
-
-
2,658
-
Less accumulated depreciation
-
-
2,159
-
Property and equipment, net
611
619
499
417
Intangible assets, net
50,000
-
-
-
Operating lease right-of-use assets
1,107
13
51
90
Other non-current assets
661
603
349
-
Total assets
828,220
410,164
466,558
476,004
Accounts payable
8,093
10,454
6,407
11,418
Accrued clinical trial costs
7,942
8,771
16,826
-
Accrued license milestone
50,000
-
-
-
Other accrued expenses
20,581
13,973
20,865
-
Operating lease liabilities, current
257
13
54
96
Accrued expenses
-
-
-
27,278
Total current liabilities
86,873
33,211
44,152
38,792
Note payable
-
127,862
126,527
125,166
Operating lease liabilities, non-current
893
-
-
-
Convertible notes
753,235
195,566
195,324
195,083
Total liabilities
841,001
356,639
366,003
359,041
Common stock, 0.001 par value 95,000,000 shares authorized as of june 30, 2026, and december 31, 2025 48,922,556 and 48,244,960 shares issued and outstanding as of june 30, 2026, and december 31, 2025, respectively
49
48
48
43
Additional paid-in capital
567,772
555,215
549,404
514,844
Accumulated deficit
-580,602
-501,738
-448,897
-397,924
Total stockholders' equity (deficit)
-12,781
53,525
100,555
116,963
Total liabilities and stockholders' equity (deficit)
828,220
410,164
466,558
476,004
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Investments$571,995K (368.73%↑ Y/Y)Cash and cashequivalents$182,049K (292.74%↑ Y/Y)Prepaid clinical trialcosts$12,996K Other current assets$8,801K (-40.20%↓ Y/Y)Total current assets$775,841K (323.72%↑ Y/Y)Intangible assets, net$50,000K Operating leaseright-of-use assets$1,107K (745.04%↑ Y/Y)Other non-currentassets$661K Property and equipment,net$611K (71.15%↑ Y/Y)Total assets$828,220K (351.12%↑ Y/Y)Accumulated deficit-$580,602K (-63.96%↓ Y/Y)Total liabilities andstockholders' equity...$828,220K (351.12%↑ Y/Y)Total stockholders'equity (deficit)-$12,781K (-128.80%↓ Y/Y)Additional paid-in capital$567,772K (42.49%↑ Y/Y)Common stock, 0.001 parvalue 95,000,000...$49K (25.64%↑ Y/Y)Total liabilities$841,001K (504.09%↑ Y/Y)Convertible notes$753,235K Total currentliabilities$86,873K (117.50%↑ Y/Y)Operating leaseliabilities, non-current$893K Accrued licensemilestone$50,000K Other accruedexpenses$20,581K Accounts payable$8,093K (-27.47%↓ Y/Y)Accrued clinical trialcosts$7,942K Operating leaseliabilities, current$257K (84.89%↑ Y/Y)

Celcuity Inc. (CELC)

Celcuity Inc. (CELC)